Previous 10 |
home / stock / th:cc / th:cc news
MONTREAL, May 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Elif McDo...
MONTREAL, May 10, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today held its annual meeting ...
Phase 1b dose established at 300 mg/m 2 or 1.5 times the therapeutic dose of docetaxel alone Expansion study will evaluate TH1902 in solid tumors with high expression of Sortilin receptor MONTREAL, May 10, 2022 (GLOBE NEWSWIRE) -- Theratechnologies In...
THERATECHNOLOGIES TO FOCUS ITS COMMERCIALIZATION ACTIVITIES ON THE NORTH AMERICAN TERRITORY Canada NewsWire MONTREAL , April 27, 2022 /CNW Telbec/ - Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical c...
MONTREAL, April 27, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ( Theratechnologies or Company ) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will focus its commercializati...
MONTREAL, April 25, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company&...
- Q1 2022 consolidated sales grew 20%, supported by 35% growth in EGRIFTA SV ® sales - TH1902 Phase 1/Part A enrollment at 300 mg/m 2 dose nearing completion, potentially enabling recruitment of larger Phase 1/Part B expansion (basket trial) in the...
Two Additional Preclinical Proof-of-concept Posters in Ovarian and Metastatic Lung Cancer Models Also Presented at the Meeting MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: TH...
MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its first quarter...
News, Short Squeeze, Breakout and More Instantly...
Theratechnologies Inc. Company Name:
TH:CC Stock Symbol:
TSXC Market:
Theratechnologies Inc. Website:
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 mi...
Firan Technology Group Corporation (FTG:CA) is expected to report for Q2 2024 Theratechnologies Inc. (TH:CA) is expected to report for Q2 2024 Transat A.T. Inc. Voting and Variable Voting Shares (TRZ:CA) is expected to report $-0.66 for Q2 2024
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...